Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

TransMedics Group Raises FY2025 Sales Guidance from $585.000M-$605.000M to $595.000M-$605.000M vs $600.848M Est

Author: Benzinga Newsdesk | October 29, 2025 03:07pm
TransMedics Group (NASDAQ:TMDX) raises FY2025 sales outlook from $585.000 million-$605.000 million to $595.000 million-$605.000 million vs $600.848 million estimate.

Posted In: TMDX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist